Respiratory Syncytial Virus disease in preterm infants in the US born at 32-35 weeks gestation not receiving immunoprophylaxis

Pediatric Infectious Disease Journal

Volumn 33, Issue 6, 2014, Pages 576-582

  Ambrose, Christopher S ^a   Anderson, Evan J ^b   Simões, Eric A F ^c   Wu, Xionghua ^f   Elhefni, Hanaa ^f   Park, C Lucy ^d   Sifakis, Frangiscos ^e   Groothuis, Jessie R ^f  

^a MEDIMMUNE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Children's Hospital Colorado   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e ASTRAZENECA   (United Kingdom)

^f NONE

Author keywords

palivizumab; Preterm infant; respiratory syncytial virus

Indexed keywords

ARTICLE; CHILD; DAY CARE; EMERGENCY WARD; GESTATIONAL AGE; HIGH RISK INFANT; HOSPITALIZATION; HUMAN; IMMUNOPROPHYLAXIS; INFANT; INFANT DISEASE; INFECTION RISK; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MEDICALLY ATTENDED ACUTE RESPIRATORY ILLNESS; NOSE SMEAR; OUTPATIENT; PREMATURITY; PRESCHOOL CHILD; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY TRACT DISEASE; RISK ASSESSMENT; RISK FACTOR; SEASONAL VARIATION; SIBLING; THROAT CULTURE; NASOPHARYNX; NEWBORN; PROSPECTIVE STUDY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; UNITED STATES; VIROLOGY;

GESTATIONAL AGE; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; NASOPHARYNX; PROSPECTIVE STUDIES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RISK FACTORS; UNITED STATES;

EID: 84901353434     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000219     Document Type: Article

References (45)

1. Simoes EA. Respiratory syncytial virus infection. Lancet. 1999;354:847-852. (Pubitemid 29415599)
2. Mutuc JD Langley GE. Respiratory syncytial virus-United States July 2007-June 2011. MMWR Morb Mortal Wkly Rep. 2011;60:1203-1206.
3. Zachariah P Shah S Gao D et al. Predictors of the duration of the respiratory syncytial virus season. Pediatr Infect Dis J. 2009;28:772-776.
4. Panozzo CA Fowlkes AL Anderson LJ. Variation in timing of respiratory syncytial virus outbreaks: lessons from national surveillance. Pediatr Infect Dis J. 2007;26(11 suppl):S41-S45. (Pubitemid 350295029)
5. Boyce TG Mellen BG Mitchel EF Jr. et al. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr. 2000;137:865-870.
6. Moler FW Khan AS Meliones JN et al. Respiratory syncytial virus morbidity and mortality estimates in congenital heart disease patients: a recent experience. Crit Care Med. 1992;20:1406-1413.
7. Horn SD Smo ut RJ. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr. 2003;143(5 suppl):S133-S141. (Pubitemid 37456911)
8. Langley GF Anderson LJ. Epidemiology and prevention of respiratory syncytial virus infections among infants and young children. Pediatr Infect Dis J. 2011;30:510-517.
9. Centers for Disease Control and Prevention. User guide to the 2010 Natality public use file. Available at: http://ftp.cdc.gov/pub/Health- statistics/NCHs/Dataset-Documentation/DVS/natality/UserGuide2010.pdf. Accessed January 21 2014.
10. Qin C Hsia J Berg CJ. Variation between last-menstrual-period and clinical estimates of gestational age in vital records. Am J Epidemiol. 2008;167:646-652. (Pubitemid 351430929)
11. Centers for Disease Control and Prevention. CDC WONDER On-line Database. Linked Birth/Infant Death Records 2007-2008. Available at: http://wonder.cdc. gov/lbd-current.html. Accessed January 21 2014.
12. Synagis (palivizumab). Full Prescribing Information MedImmune LLC Gaithersburg MD 2013.
13. American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK Baker CJ Kimberlin DW Long SS eds. Red Book: 2012 Report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village IL : American Academy of Pediatrics; 2012:609-617.
14. Committee on Infectious Diseases. From the American Academy of Pediatrics: Policy statements-modified recommendations for use of palivizumab for prevention of respirat ory syncytial virus infections. Pediatrics. 2009;124:1694-1701.
15. American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK Baker CJ Kimberlin DW Long SS eds. Red Book: 2009 Report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village IL: American Academy of Pediatrics; 2009:560-569.
16. Blanken MO Koffijberg H Nibbelke EE et al.; Dutch RSV Neonatal Network. Prosp ective validation of a prognostic model for respiratory syncytial virus bronchiolitis in late preterm infants: a multicenter birth cohort study. PLoS One. 2013;8:e59161.
17. Figueras-Aloy J Carbonell-Estrany X Quero J; IRIS Study Group. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestationa l age of 33-35 weeks in Spain. Pediatr Infect Dis J. 2004;23:815-820. (Pubitemid 40221022)
18. Figueras-Aloy J Carbonell-Estrany X Quero-Jiménez J et al.; IRIS Study Group. FLIP-2 Study: risk factors linked to re spiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J. 2008;27:788-793.
19. Law BJ Langley JM Allen U et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J. 2004;23:806-814. (Pubitemid 40221021)
20. Fryzek JP Martone WJ Groothuis JR. Trends in chronologic age and infant respiratory syncytial virus hospitalization: an 8-year cohort study. Adv Ther. 2011;28:195-201.
21. Hall CB Weinberg GA Blumkin AK et al Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age Pediatrics 2013 132 e341-e348.
22. Hall CB Weinberg GA Blumkin AK et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics. 2013;132:e341-e348. 22. Hall CB Weinberg GA Iwane MK et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360:588-598.
23. Holman RC Curns AT Cheek JE et al. Respiratory syncytial virus hospitalizations among American Indian and Alaska Native infants and the general United States infant population. Pediatrics. 2004;114:e437-e444. (Pubitemid 41529740)
24. Para more LC Ciuryla V Ciesla G et al. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics. 2004;22:275-284. (Pubitemid 38553698)
25. Stockman LJ Curns AT Anderson LJ et al. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States 1997-2006. Pediatr Infect Dis J. 2012;31:5-9.
26. Legoff J Kara R Moulin F et al. Evaluation of the one-step multiplex real-time reverse transcription-PCR ProFlu-1 assay for detection of influenza A and influenza B viruses and respiratory syncytial viruses in children. J Clin Microbiol. 2008;46:789-791. (Pubitemid 351231339)
27. The IMpact-RSV Study Group. Palivizumab a humanized respiratory syncytial virus monoclonal antibody reduces hospitalization from respiratory syncytial virus infection in high-r isk infants. Pediatrics. 1998;102:531-537.
28. Heikkinen T Valkonen H Lehtonen L et al. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizum ab prophylaxis. Arch Dis Child Fetal Neonatal Ed. 2005;90:F64-F68. (Pubitemid 40040210)
29. Forbes ML Hall CB Jackson A et al. Comparative costs of hospitalisation among infants at high risk for respiratory syncytial virus lower respiratory tract infection during the first year of life. J Med Econ. 2010;13:136-141.
30. Carbonell-Estrany X Quero J; IRIS Study Group. Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr In fect Dis J. 2001;20:874-879. (Pubitemid 32880323)
31. McEvoy C Venigalla S Schilling D et al. Respiratory function in healthy late preterm infants delivered at 33-36 weeks of gestation. J Pediatr. 2013;162:464-469.
32. Hoo AF Dezateux C Henschen M et al. Development of airway function in infancy after preterm delivery. J Pediatr. 2002;141:652-658. (Pubitemid 35292763)
33. Friedrich L Pitrez PM Stein RT et al. Growth rate of lung function in healthy preterm infants. Am J Respir Crit Care Med. 2007;176:1269-1273. (Pubitemid 350256481)
34. Colin AA McEvoy C Casti le RG. Respiratory morbidity and lung function in preterm infants of 32 to 36 weeks'gestational age. Pediatrics. 2010;126:115-128.
35. Yeung CY Hobbs JR. Serum-gamma-G-globulin levels in normal premature post-mature and "small-for-dates" newborn babies. Lancet. 1968;1:1167-1170.
36. Simoes EA. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr. 2003;143(5 suppl):S118-S126. (Pubitemid 37456909)
37. Lacaze-Masmonteil T Truffert P Pinquier D et al. Lower respiratory tract illness and RSV prophylaxis in very premature infants. Arch Dis Child. 2004;89:562-567.
38. Simoes EA King SJ Lehr MV et al. Preterm twins and triplets. A high-risk group for severe respiratory syncytial virus infection. Am J Dis Child. 1993;147:303-306. (Pubitemid 23077289)
39. Resch B Pasnocht A Gusenleitner W et al. Rehospitalisations for respiratory disease and respiratory syncytial virus infection in preterm infants of 29-36 weeks gestational age. J Infect. 2005;50:397-403. (Pubitemid 40692024)
40. Park HW Lee BS Kim AR et al. Epidemiology of respiratory syncytial virus infection in infants born at less than thirty-five weeks of gestational age. Pediatr Infect Dis J. 2012;31:e99-e104.
41. Liese JG Grill E Fischer B et al.; Munich RSV Study Group. Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Eu r J Pediatr. 2003;162:230-236. (Pubitemid 36437755)
42. Law B Macdonald N Langley J et al. Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: What are we trying to prevent P aediatr Child Health. 1998;3:402-404.
43. Winterstein AG Knox CA Kubilis P et al.Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort study JAMA Pediatr. 2013 167 1118-1124.
44. Carbonell X Fullarton JR Gooch KL et al The evolution of risk factors for respiratory syncytial virus-related hospitalisation in infants born at 32-35 weeks'gestational age: time-based analysis using data from the FLIP-2 study. J Perinat Med. 2012;40:685-691.
45. Olsen IE Lawson ML Meinzen-Derr J et al. Use of a body proportionality index for growth assessment of preterm infants. J Pediatr. 2009;154: 486-491.